Skip to Content

Trastuzumab Emtansine (Kadcyla) Versus Paclitaxel and Trastuzumab for Early Stage Breast Cancer

A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (TDM-1) vs. Paclitaxel in Combination with Trastuzumab for Stage 1 HER2 Neu Positive Breast Cancer

Objective

Compare the side effects between trastuzumab emtansine and paclitaxel in combination with trastuzumab. It is believed the trastuzumab emtansine will be lower.

Inclusion Criteria:
Patients who have had surgery to remove breast cancer that is 2 cm or less. Her 2 neu positive.

Exclusion Criteria:
No breast cancer lymph nodes under the arm.

IRB Protocol Number
ATEMPT: 13-048

Clinical Trial Categories

  • Breast Cancer
Contact
Margaret White, RN OCN, CC at 603-232-8908

Location

  • Payson Center for Cancer Care
    250 Pleasant Street
    Concord, NH 03301
    Main: 603-230-6000